1) Adams EH, Breiner S, Cicero TJ, Geller A, Inciardi JA, Schnoll SH, Senay EC, Woody GE:A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage 31:465-476, 2006
2) Andersen G, Vestergaard K, Ingeman-Nielsen M, Jensen TS:Incidence of central post-stroke pain. Pain 61:187-194, 1995
3) Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P:EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13:1153-1169, 2006
4) Bamigbade TA, Davidson C, Langford RM, Stamford JA:Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin(5-HT)efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 79:352-356, 1997
5) Bowsher D:Cerebrovascular disease:sensory consequences of stroke. Lancet 341:156, 1993
6) Bowsher D:Central pain:clinical and physiological characteristics. J Neurol Neurosurg Psychiatry 61:62-69, 1996
7) Bowsher D, Leijon G, Thuomas KA:Central poststroke pain:correlation of MRI with clinical pain characteristics and sensory abnormalities. Neurology 51:1352-1358, 1998
8) Cicero TJ, Adams EH, Geller A, Inciardi JA, Muñoz A, Schnoll SH, Senay EC, Woody GE:A postmarketing surveillance program to monitor Ultram(tramadol hydrochloride)abuse in the United States. Drug Alcohol Depend 57:7-22, 1999
9) Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS:Pharmacologic management of neuropathic pain:evidence-based recommendations. Pain 132:237-251, 2007
10) Ko SH, Kwon HS, Yu JM, Baik SH, Park IB, Lee JH, Ko KS, Noh JH, Kim DS, Kim CH, Mok JO, Park TS, Son HS, Cha BY:Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. Diabet Med 27:1033-1040, 2010
11) Leijon G, Boivie J:Central post-stroke pain:a controlled trial of amitriptyline and carbamazepine. Pain 36:27-36, 1989
12) Loeser JD, Treede RD:The Kyoto protocol of IASP Basic Pain Terminology. Pain 137:473-477, 2008
13) Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T, Morley-Forster PK, Stinson J, Boulanger A, Peng P, Finley GA, Taenzer P, Squire P, Dion D, Cholkan A, Gilani A, Gordon A, Henry J, Jovey R, Lynch M, Mailis-Gagnon A, Panju A, Rollman GB, Velly A:Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 12:13-21, 2007
14) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン作成ワーキンググループ(編):神経障害性疼痛薬物療法ガイドライン.真興交易,東京,2011
15) Reimann W, Hennies HH:Inhibition of spinal noradrenaline uptake in rats by the centrally acting analgesic tramadol. Biochem Pharmacol 47:2289-2293, 1994
16) Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D:Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 348:1223-1232, 2003
17) Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS:Lamotrigine for central poststroke pain. A randomized controlled trial. Neurology 56:184-190, 2001
18) Vranken JH, Dijkgraaf MGW, Kruis MR, van der Vegt MH, Hollmann MW, Heesen M:Pregabalin in patients with central neuropathic pain:a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 136:150-157, 2008
19) Yalcin I, Aksu F, Bodard S, Chalon S, Belzung C:Antidepressant-like effect of tramadol in the unpredictable chronic mild stress procedure:possible involvement of the noradrenergic system. Behav Pharmacol 18:623-631, 2007
20) 山本隆充(編):ペインクリニックVol.33別冊春号.真興交易,東京,2012, S83-88